Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

5Total

N/A(3)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00486044Phase 2Completed

Evaluating Simvastatin's Potential Role in Therapy

Role: collaborator

NCT03071315Completed

Economic Evaluation Comparing CCT With MMT in Hai Phong City, Vietnam

Role: collaborator

NCT01595464Not ApplicableCompleted

Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza

Role: collaborator

NCT01595477Not ApplicableCompleted

Mind-Body Skills Groups for the Treatment of War-Related Trauma in Children in Gaza

Role: collaborator

NCT01595490Not ApplicableCompleted

Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza

Role: collaborator

NCT00779337Phase 1Completed

Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

Role: collaborator

All 6 trials loaded